12:00 AM
Nov 09, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nab-rapamycin: Phase II started

AADi began an open-label, U.S. pivotal Phase II trial to evaluate ABI-009 in about 35 patients. AADi has exclusive, worldwide rights to develop and commercialize ABI-009 from...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >